
 **HFCI Gastrointestinal and Neuroendocrine Multidisciplinary Symposium (5/14/22) | 5/14/2022 7:45:00 AM The Dearborn Inn**

Gastrointestinal and Neuroendocrine HFCI Multidisciplinary Symposium

**Program Goal**

1 To understand the impact of recent data from clinical trials on GI and Neuroendocrine Cancer patient care.

2 To become informed on best practices in integrated multimodality therapies for patients with Gastrointestinal cancers and Neuroendocrine tumors.

3 To use molecular diagnostic studies in the management of patients with Gastrointestinal and Neuroendocrine tumors.

**Target Audience** Medical Oncology

**Faculty**

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Name of Ineligible Company(s) / Nature of Relationship(s)** |
| Tressa Cuschieri, BBA | Activity Administrator |  |
| Kisha McPherson, MHSA | Activity Administrator | Nothing to disclose - 02/07/2022 |
| Hannah Beels, BHSA | CME Reviewer | Nothing to disclose - 03/21/2022 |
| Crystal M Gyiraszin, MS | CME Reviewer | Nothing to disclose - 12/14/2021 |
| Michelle Clark, BA | CME Specialist | Nothing to disclose - 01/28/2022 |
| Philip Philip, MD, PhD | Course Director, Faculty | Honoraria-Advisor, Speaker Beureau, |Consulting Fee-Stemline (Relationship has ended)|Honoraria-Lilly (Relationship has ended)|Grant or research support-Karyopharm (Relationship has ended)|Advisor-Pfizer (Relationship has ended)|Advisor-Seattle Genetics|Consulting Fee-Bayer|Grant or research support-Carcept (Relationship has ended)|Honoraria-Daiichi|Honoraria-Erytech|Honoraria-Incyte|Honoraria-Ipsen|Honoraria-Merck|Honoraria-Novocure (Relationship has ended)|Grant or research support-Rafael (Relationship has ended)|Honoraria-Genetech|Consulting Fee-Trisauls|Advisor-Boston Pharmaceuticals (Relationship has ended)|Honoraria-Servier - 01/08/2022 |
| Richard Berri, MD | Faculty | Nothing to disclose - 02/22/2022 |
| Dhananjay Chitale, MD | Faculty | Nothing to disclose - 03/28/2022 |
| Shirish Gadgeel, MD | Faculty | Consulting Fee-Astra-Zeneca, Genentech-Roche, Pfizer, Mirati, Bristol Myers-Squibb, Takeda, Janssen, Daichii, Blueprint, Lilly, Novartis, Merck (Relationship has ended) - 04/11/2022 |
| Gazala Khan, MD | Faculty | Membership on Advisory Committees or Review Panels, Board Membership, etc.-Eisai, Incyte, Helsinn - 04/22/2022 |
| Steve H Kim, MD, FACS | Faculty | Nothing to disclose - 03/31/2022 |
| Shunji Nagai, MD | Faculty | Nothing to disclose - 03/01/2022 |
| Parag Parikh, MD | Faculty | Speakers Bureau-Viewray|Grant or research support-Viewray|Stocks or stock options, excluding diversified mutual funds-Nuvaira - 02/28/2022 |
| Vaibhav Sahai, MBBS | Faculty | Membership on Advisory Committees or Review Panels, Board Membership, etc.-Astrazeneca|Membership on Advisory Committees or Review Panels, Board Membership, etc.-GlaxoSmithKline (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Helsinn (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Histosonics|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Incyte|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Klus (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Kinnate (Relationship has ended)|Honoraria-Lynx Group|Membership on Advisory Committees or Review Panels, Board Membership, etc.-QED (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Rafael Pharmaceuticals - 02/12/2022 |
| Reena Salgia, MD | Faculty | Nothing to disclose - 02/22/2022 |
| Rupen Shah, MD | Faculty | Nothing to disclose - 03/01/2022 |
| Michael S Simon, MD, MPH | Faculty | Nothing to disclose - 02/14/2022 |
| Sumit Singla, MD | Faculty | Consulting Fee-Boston Scientific - 03/01/2022 |
| Mark Zalupski, MD | Faculty | Nothing to disclose - 02/17/2022 |

**ACCREDITATION STATEMENT: Henry Ford Health System** is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

**DESIGNATION STATEMENT: Henry Ford Health System** designates this educational activity for a maximum of 6.00 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

**FACULTY/PLANNING COMMITTEE DISCLOSURE STATEMENT:** In Compliance with the ACCME Standards for Commercial Support, all individuals in a position to control/influence the content of this activity are required to disclose relevant financial interests of their own or spouse or partners with any ACCME defined commercial interests for the past 24 months and/or any non-FDA approved use of a drug or a device that is included in the presentation. All relevant financial relationships have been mitigated.

**ACCESSIBILITY STATEMENT:** Henry Ford Health System Office of Continuing Medical Education is committed to ensuring that its programs, services, goods and facilities are accessible to individuals with disabilities as specified under Section 504 of the Rehabilitation Act of 1973 and the Americans with Disabilities Amendments Act of 2008. If you have needs that require special accommodations, including dietary concerns, please contact the CME Conference Coordinator.